Flora Vayr1, Marion Montastruc2, Frédéric Savall3,4, Fabien Despas5,6,7,8, Elodie Judic1, Maud Basso9, Charlotte Dunet9, Florence Dalenc2, Guy Laurent7,10, Jean Marc Soulat1,7, Fabrice Herin11,12. 1. Service des Maladies Professionnelles et Environnementales, CHU Toulouse, F-31000, Toulouse, France. 2. Service d'Oncologie, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole, F-31000, Toulouse, France. 3. Service de Médecine Légale, CHU Toulouse, F-31000, Toulouse, France. 4. Laboratoire d'Anthropologie Moléculaire et Imagerie de Synthèse, CNRS, UMR 5288, Université de Toulouse III, F-31000, Toulouse, France. 5. Service de Pharmacologie Médicale et Clinique, CHU Toulouse, F-31000, Toulouse, France. 6. Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, Université Paul Sabatier, F-31000, Toulouse, France. 7. INSERM UMR 1027, Université de Toulouse III, F-31000, Toulouse, France. 8. CIC INSERM 1436, Université et CHU Toulouse, F-31000, Toulouse, France. 9. Département de la Recherche et de l'Innovation, CHU Toulouse, F-31000, Toulouse, France. 10. Service d'Hématologie, CHU Toulouse, Institut Universitaire du Cancer de Toulouse - Oncopole, F-31000, Toulouse, France. 11. Service des Maladies Professionnelles et Environnementales, CHU Toulouse, F-31000, Toulouse, France. herin.f@chu-toulouse.fr. 12. INSERM UMR 1027, Université de Toulouse III, F-31000, Toulouse, France. herin.f@chu-toulouse.fr.
Abstract
PURPOSE: The objective of our study was to assess the rate of work adjustments 1 year after the diagnosis in a population of female breast cancer (BC) survivors, in the context of the French system of social protection. We also characterised these adjustments and their influence on the reduction of professional exclusion of patients 1 year after the diagnosis. METHODS: This observational, prospective study was conducted from February 2015 to April 2016 among female patients with BC. Inclusion criteria were women aged between 18 and 65 years, treated for BC and integrated into the labour market at the time of diagnosis (working or on sick leave). Exclusion criteria were metastatic BC, retired patients and refusal to participate. A 1-year follow-up was scheduled, and data collection was performed with questionnaires. RESULTS: In total, 213 patients were included between February 2015 and April 2016. One year after the diagnosis (T1), among 185 BC survivors, 78 (42.2%) patients were working. Among them, 13 patients did not interrupt their occupational activity and 65 returned to work after a period of sick leave. Sixty-four patients returned to work after the end of chemotherapy (after 6 months), and one returned to work before this therapeutic threshold. Sixty-six patients (35.7%) benefited from at least one adjustment of their work conditions to facilitate their return to work (RTW) or maintenance at work: working hours were decreased for 43 patients, and workstation changes were performed for 22 patients. An occupational health physician was involved for some patients; work adjustments were prescribed to 42 patients, 7 patients had medical restrictions for physical reasons and 4 patients had restrictions for psychological reasons. Forty-three patients benefited from part-time work prescribed for therapeutic reasons. CONCLUSIONS: Referral to occupational health physicians and work adjustments remain limited in the process of RTW or maintenance at work after BC in France, despite their positive impact.
PURPOSE: The objective of our study was to assess the rate of work adjustments 1 year after the diagnosis in a population of female breast cancer (BC) survivors, in the context of the French system of social protection. We also characterised these adjustments and their influence on the reduction of professional exclusion of patients 1 year after the diagnosis. METHODS: This observational, prospective study was conducted from February 2015 to April 2016 among female patients with BC. Inclusion criteria were women aged between 18 and 65 years, treated for BC and integrated into the labour market at the time of diagnosis (working or on sick leave). Exclusion criteria were metastatic BC, retired patients and refusal to participate. A 1-year follow-up was scheduled, and data collection was performed with questionnaires. RESULTS: In total, 213 patients were included between February 2015 and April 2016. One year after the diagnosis (T1), among 185 BC survivors, 78 (42.2%) patients were working. Among them, 13 patients did not interrupt their occupational activity and 65 returned to work after a period of sick leave. Sixty-four patients returned to work after the end of chemotherapy (after 6 months), and one returned to work before this therapeutic threshold. Sixty-six patients (35.7%) benefited from at least one adjustment of their work conditions to facilitate their return to work (RTW) or maintenance at work: working hours were decreased for 43 patients, and workstation changes were performed for 22 patients. An occupational health physician was involved for some patients; work adjustments were prescribed to 42 patients, 7 patients had medical restrictions for physical reasons and 4 patients had restrictions for psychological reasons. Forty-three patients benefited from part-time work prescribed for therapeutic reasons. CONCLUSIONS: Referral to occupational health physicians and work adjustments remain limited in the process of RTW or maintenance at work after BC in France, despite their positive impact.
Entities:
Keywords:
Breast cancer; Chemotherapy; Employment; Neoplasms; Occupation
Authors: Linda M Frazier; Virginia A Miller; Brigitte E Miller; Douglas V Horbelt; James E Delmore; Carolyn R Ahlers-Schmidt Journal: J Support Oncol Date: 2009 Nov-Dec
Authors: Khalid M Kamal; Jordan R Covvey; Ankur Dashputre; Somraj Ghosh; Surbhi Shah; Monali Bhosle; Christopher Zacker Journal: J Manag Care Spec Pharm Date: 2017-02
Authors: Ophélie Wilczynski; Anthony Boisbouvier; Lise Radoszycki; François-Emery Cotté; Anne-Françoise Gaudin; Hervé Lemasson Journal: J Med Internet Res Date: 2022-01-11 Impact factor: 5.428